Sentence examples for multiple tyrosine kinases from inspiring English sources

SHP2 provides a parallel survival input downstream of multiple tyrosine kinases that promote resistance to ALK inhibitors.

A receptor tyrosine kinase (RTK) array study revealed promising inhibition of multiple tyrosine kinases such as IGF-1R, Tyro3 and EphA2 phosphorylation.

Sunitinib, an oral, multi-targeted, small-molecule inhibitor of multiple tyrosine kinases, is known to inhibit angiogenesis and therefore might decrease progression of urothelial cancer.

Results from a Phase III clinical trial with sorafenib, an inhibitor of multiple tyrosine kinases, show only a 2% response rate; however, a statistically significant improvement in progression-free survival was observed.

Recently in idiopathic pulmonary fibrosis, efficacy of Nintedanib (multiple tyrosine kinases inhibitor) and pirfenidone (an anti-fibrotic and anti-inflammatory drug) has been reported in improving lung function [41],[41].

However, the imatinib targets involved in modulation of vascular permeability have not been well-characterized, as imatinib inhibits multiple tyrosine kinases not only in endothelial cells and pericytes but also immune cells important for disorders associated with pathological inflammation and abnormal vascular permeability.

Kondo T, Nagamura-Inoue T, Tojo A, Nagamura F, Uchida N, Nakamae H, et al. Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.

Decorin, a leucine-rich proteoglycan that is produced by decidual cells, limits invasion and endovascular differentiation of extravillous trophoblast cells during early placentation by binding to multiple tyrosine kinase receptors, in particular, vascular endothelial growth factor receptor-2.

The newly-synthesized compounds showed huge diversity of antiproliferative potency due to variety of metal ions and length of alkyl chains, among which the Zn II) and Cr III) complexes exhibited comparable antiproliferative activities with amonafide via multiple tyrosine kinase inhibition.

Here we analyzed plasma miRs in patients with hormone receptor positive, metastatic breast cancer with prior disease progression during aromatase inhibitor therapy (n = 8) in a phase I/II trial with the multiple tyrosine kinase inhibitor dovitinib (TKI258).

Thus, by antagonistically targeting multiple tyrosine kinase receptors, decorin reduces primary tumor development and progression [11].